propranolol has been researched along with Depression, Involutional in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol or a placebo was administered 90 min before a brief memory reactivation session, once a week for 6 consecutive weeks." | 3.01 | Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial. ( Birmes, P; Bourcier, A; Dupuch, L; El Hage, W; Jasse, L; Lamy, P; Roullet, P; Thalamas, C; Vaiva, G; Véry, E; Yrondi, A, 2021) |
| " Here, we investigated the roles of Cyp1a2 and Cyp2d on DLX pharmacokinetic profile and tissue distribution using a Cyp1a2 knockout (Cyp1a2-KO) mouse model together with a Cyp2d inhibitor (propranolol)." | 1.91 | The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. ( Barzi, M; Bissig, KD; Boyd, SR; Hakenjos, JM; Li, F; MacKenzie, KR; Qin, X; Xie, C; Young, DW, 2023) |
| "A 31-year-old man with major depressive disorder was found dead in his dormitory room." | 1.46 | Fatal Self-Poisoning With Massive Propranolol Ingestion in a Young Male Physician. ( Srettabunjong, S, 2017) |
| "Propranolol was effective in treating acute pathological panic, but modest doses of the drug administered for brief periods of time did not alleviate chronic panic attacks associated with agoraphobia." | 1.26 | The treatment of pathological panic states with propranolol. ( Defrancisco, D; Heiser, JF, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qin, X | 2 |
| Xie, C | 2 |
| Hakenjos, JM | 2 |
| MacKenzie, KR | 2 |
| Boyd, SR | 2 |
| Barzi, M | 2 |
| Bissig, KD | 2 |
| Young, DW | 2 |
| Li, F | 2 |
| Fujita, S | 1 |
| Yoshida, S | 1 |
| Matsuki, T | 1 |
| Jaiswal, MK | 1 |
| Seki, K | 1 |
| Roullet, P | 1 |
| Vaiva, G | 1 |
| Véry, E | 1 |
| Bourcier, A | 1 |
| Yrondi, A | 1 |
| Dupuch, L | 1 |
| Lamy, P | 1 |
| Thalamas, C | 1 |
| Jasse, L | 1 |
| El Hage, W | 1 |
| Birmes, P | 1 |
| Srettabunjong, S | 1 |
| Räsänen, P | 1 |
| Hakko, H | 1 |
| Tiihonen, J | 1 |
| Heiser, JF | 1 |
| Defrancisco, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol: A Randomized Placebo-controlled Trial. PPP[NCT04985344] | Phase 3 | 92 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | ||
| Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial[NCT01713556] | Phase 2 | 87 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for propranolol and Depression, Involutional
| Article | Year |
|---|---|
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Humans; Propranolol; Stress Disorder | 2021 |
5 other studies available for propranolol and Depression, Involutional
| Article | Year |
|---|---|
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Topics: Animals; Central Nervous System Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Depressive | 2023 |
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Topics: Animals; Central Nervous System Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Depressive | 2023 |
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Topics: Animals; Central Nervous System Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Depressive | 2023 |
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Topics: Animals; Central Nervous System Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Depressive | 2023 |
The α1-adrenergic receptors in the amygdala regulate the induction of learned despair through protein kinase C-beta signaling.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Amygdala; Animals; Depressive | 2021 |
Fatal Self-Poisoning With Massive Propranolol Ingestion in a Young Male Physician.
Topics: Adrenergic beta-Antagonists; Adult; Depressive Disorder, Major; Gastrointestinal Contents; Humans; M | 2017 |
Mitchell B. Balter Award--1998. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients.
Topics: Adrenergic beta-Antagonists; Atenolol; Depressive Disorder, Major; Disability Evaluation; Drug Thera | 1999 |
The treatment of pathological panic states with propranolol.
Topics: Acute Disease; Adult; Agoraphobia; Anxiety Disorders; Chronic Disease; Depression; Depressive Disord | 1976 |